•
Jun 30, 2022
Viking Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $17.4 million, or $0.23 per share, for the second quarter ended June 30, 2022. The company ended the quarter with $169 million in cash, cash equivalents and short-term investments.
Clinical data from three programs is anticipated in the next twelve months.
VK2809 Phase 2b VOYAGE study is advancing, with completion of enrollment expected in 4Q 2022.
Phase 1 study of dual GLP-1/GIP agonist VK2735 is ongoing, with initial results expected by year-end.
Phase 1b study of VK0214 in X-ALD to resume, with results expected in 1H 2023.